renal cell carcinoma

Arcus and AstraZeneca enter trial collaboration for renal cancer treatment
Clinical Trials Arena
Thu, 10/3/24 - 10:37 am
Arcus Biosciences
AstraZeneca
renal cancer
casdatifan
renal cell carcinoma
ESMO: Despite positive trial, Merck's Welireg still comes up short in overall survival
Fierce Pharma
Fri, 09/13/24 - 11:12 am
Merck
Welireg
renal cell carcinoma
Novartis
Afinitor
ESMO
clinical trials
Allogene’s CAR T clinical trial advances with CIRM grant
Clinical Trials Arena
Mon, 04/29/24 - 11:07 am
Allogene Therapeutics
funding
CAR-T
ALLO-316
renal cell carcinoma
Merck partners with HiberCell for Phase Ib renal carcinoma trial
Clinical Trials Arena
Wed, 12/6/23 - 10:29 am
Merck
HiberCell
Welireg
HC-7366
renal cell carcinoma
Merck’s Welireg Clears Phase III Primary Endpoint in Renal Cell Carcinoma
BioSpace
Fri, 08/18/23 - 10:13 am
Merck
Welireg
renal cell carcinoma
clinical trials
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Tue, 05/30/23 - 09:18 pm
Merck
Eisai
ASCO 2023
Lenvima
Keytruda
renal cell carcinoma
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
BioSpace
Fri, 03/3/23 - 12:01 pm
Roche
Exelixis
renal cell carcinoma
Tecentriq
Cabometyx
clinical trials
BMS and Nektar Shutter Combination Cancer Development Program
BioSpace
Fri, 04/15/22 - 01:42 pm
Bristol Myers Squibb
Nektar Therapeutics
bladder cancer
renal cell carcinoma
bempegaldesleukin
Merck's Keytruda scores first win in adjuvant kidney cancer, giving it a leg up on checkpoint inhibitor rivals
Endpoints
Thu, 11/18/21 - 10:37 am
Merck
Keytruda
adjuvant immunotherapy
renal cell carcinoma
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Thu, 08/12/21 - 12:35 pm
Merck
Keytruda
advanced renal cell carcinoma
renal cell carcinoma
Eisai
Lemvima
FDA
Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
Fierce Pharma
Thu, 04/8/21 - 11:13 am
Merck
Keytruda
renal cell carcinoma
kidney cancer
clinical trials
Merck wins priority review for rare carcinoma drug belzutifan, the centerpiece of $1B+ Peloton buyout
Endpoints
Tue, 03/16/21 - 10:54 am
Merck
Peloton Therapeutics
belzutifan
M&A
PT2977
renal cell carcinoma
priority review
FDA
Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer
BioSpace
Tue, 02/16/21 - 11:12 am
Merck
ASCO GU
Keytruda
Eisai
Lenvima
renal cell carcinoma
Calithera flunks phase 2 cancer trial, axes 35% of staff
Fierce Biotech
Mon, 01/4/21 - 10:25 am
Calithera Biosciences
clinical trials
telaglenastat
renal cell carcinoma
layoffs
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
Yahoo/Zacks.com
Tue, 08/25/20 - 11:19 am
Exelixis
Cabometyx
FDA
kidney cancer
renal cell carcinoma
Bristol-Myers Squibb
Opdivo
Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Endpoints
Mon, 04/20/20 - 11:59 pm
Bristol-Myers Squibb
Opdivo
Exelixis
Cabometyx
renal cell carcinoma
kidney cancer
clinical trials
After digging through discards, biotech startup is making a $45M bet it can fix a failed cancer therapy
Endpoints
Thu, 02/20/20 - 10:39 am
Active Biotech
naptumomab
renal cell carcinoma
NeoTX
Opdivo delivers superior five-year survival results in renal cell carcinoma
Pharmaceutical Business Review
Mon, 02/17/20 - 10:33 am
Bristol-Myers Squibb
Opdivo
clinical trials
renal cell carcinoma
AstraZeneca dumps phase 3 renal cell carcinoma program
Fierce Biotech
Thu, 10/24/19 - 10:23 am
AstraZeneca
savolitinib
renal cell carcinoma
Renal Cell Carcinoma Space in Focus: Some Key Developments
Yahoo/Zacks.com
Sat, 09/14/19 - 11:18 am
renal cell carcinoma
kidney cancer
Exelixis
Roche
Merck
Aveo Oncology

Pages